Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study

INTRODUCTION: Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-threatening disease caused by excessive activation of part of the immune system called complement. Eculizumab is an effective treatment, controlling aHUS in 90% of patients. Due to the risk of relapse, lifelong treatment is cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunn, Sarah, Brocklebank, Victoria, Bryant, Andrew, Carnell, Sonya, Chadwick, Thomas J, Johnson, Sally, Kavanagh, David, Lecouturier, Jan, Malina, Michal, Moloney, Eoin, Oluboyede, Yemi, Weetman, Christopher, Wong, Edwin Kwan Soon, Woodward, Len, Sheerin, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Renal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486193/
https://www.ncbi.nlm.nih.gov/pubmed/36123058
http://dx.doi.org/10.1136/bmjopen-2021-054536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486193/
https://www.ncbi.nlm.nih.gov/pubmed/36123058
http://dx.doi.org/10.1136/bmjopen-2021-054536

Ejemplares similares